The Clorox Company
NYSE:CLXHousehold & Personal Products
-$2.54 today
- Market cap
- $13.13B
- Beta
- 0.55
- P/E (TTM)
- 15.2
- EPS (TTM)
- $6.23
- Dividend yield
- 5.22%
Volume 2.16M
Average 2.84M
CLX Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
The Clorox CompanyNYSE: CLX
Financing Cash Flow · Q1 FY2027 · quarter ended Sep 2026
Financing cash flow grows, but more slowly than its trailing trend
Q1 FY2027 financing cash flow of $68M (cash outflow) rose 15.3% year over year, behind the +322.4% change in trailing-twelve-month financing cash flow.
Context
- Financing cash flow amounted to 24.8% of revenue in FY2026, up 11.8 pp from a year earlier.
- Financing cash flow increased in 2 of the last 3 fiscal years.
- FY2026 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +15.3% toward the trailing-twelve-month pace of +322.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2026
- 1.67B USD
- Year-over-year change
- +280.5%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2026 | 2026-06-30 | 1.67B | +280.5% |
| FY2025 | 2025-06-30 | (924M) | -41.1% |
| FY2024 | 2024-06-30 | (655M) | +13.0% |
| FY2023 | 2023-06-30 | (753M) | -9.3% |
| FY2022 | 2022-06-30 | (689M) | — |
Financing Cash Flow vs competitors
How CLX compares with its peers on the latest reported figures
- Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +322.4% is the 2nd highest of 10, against a peer median of -1.8%.
- Financing cash flow amounts to 23.1% of revenue for CLX, versus a peer median of 12.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $11.08B USD | -29.2% | +6.0% | 12.6% | |
| FY2025 | €6.81B EUR | -1.8% | -8.5% | 13.5% | |
| LTM Sep 2026 | $3.63B USD | +14.5% | +50.7% | 17.1% | |
| LTM Sep 2026 | $2.43B USD | +56.3% | +5.1% | 15.6% | |
| LTM Sep 2026 | $1.66B USD | +322.4% | — | 23.1% | |
| LTM Jun 2026 | $820M USD | +124.5% | +7.4% | 5.0% | |
| LTM Sep 2026 | $766.4M USD | -6.4% | +112.6% | 12.3% | |
| LTM Jun 2026 | $311M USD | -9.9% | +12.1% | 8.2% | |
| LTM Mar 2026 | $269.9M USD | +468.2% | +19.5% | 12.8% | |
| LTM Jun 2026 | $154M USD | -40.6% | — | 5.4% | |
| LTM Dec 2025 | $136.69M USD | — | — | — | |
| Peer median (excluding CLX) | — | -1.8% | +9.8% | 12.6% | |
Competitors are the stored peer set for CLX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Jun 2022 | FY2023 Jun 2023 | FY2024 Jun 2024 | FY2025 Jun 2025 | FY2026 Jun 2026 |
|---|---|---|---|---|---|
| Net Income | 471M | 161M | 292M | 824M | 601M |
| Depreciation & Amortization | 224M | 236M | 235M | 219M | 247M |
| Deferred Income Tax | 5M | (149M) | (100M) | (18M) | 81M |
| Stock-Based Compensation | 52M | 73M | 74M | 81M | 48M |
| Change in Working Capital | (99M) | 354M | (241M) | (211M) | 118M |
| Accounts Receivables | (84M) | (13M) | (34M) | (145M) | 151M |
| Inventory | (18M) | 58M | 55M | 63M | (71M) |
| Accounts Payables | (47M) | 157M | (140M) | (124M) | 38M |
| Other Working Capital | 50M | 152M | (122M) | (5M) | 0 |
| Other Non-Cash Items | 133M | 483M | 435M | 86M | (483M) |
| Operating Cash Flow | 786M | 1.16B | 695M | 981M | 612M |
| Capital Expenditures | (251M) | (228M) | (212M) | (220M) | (207M) |
| Acquisitions (Net) | 0 | 0 | 17M | 128M | (2.1B) |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 22M | 5M | 20M | (2M) | 10M |
| Investing Cash Flow | (229M) | (223M) | (175M) | (94M) | (2.3B) |
| Debt Repayment | (83M) | (188M) | (45M) | 0 | 2.57B |
| Common Stock Issued | 5M | 33M | 1M | 26M | (23M) |
| Common Stock Repurchased | (25M) | 0 | 0 | (332M) | (256M) |
| Dividends Paid | (571M) | (583M) | (595M) | (602M) | (602M) |
| Other Financing Activities | (15M) | (15M) | (16M) | (16M) | (16M) |
| Financing Cash Flow | (689M) | (753M) | (655M) | (924M) | 1.67B |
| Effect of Forex Changes | (6M) | 2M | (26M) | 2M | (2M) |
| Net Change in Cash | (138M) | 184M | (161M) | (35M) | (23M) |
| Free Cash Flow | 535M | 930M | 483M | 761M | 405M |
The Clorox Company
NYSE:CLX
Intrinsic Alpha fair value
Locked
Current Price
$108.39
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.